Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021
Shots:
- The company reported the results from a study based on the structural and functional analysis of SB11- a proposed biosimilar referencing Lucentis (ranibizumab)
- The analytical assessment demonstrated that structural- physicochemical characterization i.e. amino acid sequence- post-translational modifications- higher order structure- and size and charge variants of SB11 were similar to Lucentis
- The SB11 is also functionally similar to Lucentis based on a set of bioassays and binding assays covering a broad range of VEGF-related functional activities. SB11 is under review by the US FDA and EMA
Ref: Globenewswire | Image: Samsung Bioepis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com